Skip to main content
SpringerLink
Log in

Malignant Peritoneal Mesothelioma

  • Chapter
Book cover Regional Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Malignant peritoneal mesothelioma (MPM) is an incurable disease. It represents approximately 15% of all mesotheliomas and has a male predominance. It has a known relationship to asbestos, but most patients present with no known history of exposure. Simian virus 40 (SV40) exposure is potentially another risk factor, although the relationship is not entirely supported. Patients usually present with vague symptoms. Diagnosis is usually made on the basis of a CT scan and percutaneous or open biopsy. The disease remains confined to the abdominal cavity until very late in the disease course. Ascites is a frequent sign; morbidity and mortality are usually a consequence of disease progression within the abdominal cavity. Systemic chemotherapy and radiation have not yet been shown to have much influence over the natural history of the disease. In selected patients, surgical cytoreduction with intraoperative hyperfhermic peritoneal chemotherapy is associated with long-term survival. A summary of clinical experience with surgical cytoreduction and intraoperative intraperitoneal chemotherapy for MPM is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–621, xi.

    Article  Google Scholar 

  2. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–4567.

    Article  PubMed  CAS  Google Scholar 

  3. Cancer Surveillance. 2005. Ref Type: Internet Communication

    Google Scholar 

  4. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in aregistry of 180 patients, the Dana Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988;6:147–153.

    PubMed  CAS  Google Scholar 

  5. SEER. Cancer Statistics Review—Mesothelioma fast stats. 2005.

    Google Scholar 

  6. Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med 2004;61:438–441.

    Article  PubMed  CAS  Google Scholar 

  7. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004;14:469–477, viii.

    PubMed  Google Scholar 

  8. Landrigan PJ. Asbestos—still a carcinogen. N Engl J Med 1998;338:1618–1619.

    Article  PubMed  CAS  Google Scholar 

  9. Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000;44:565–601.

    PubMed  CAS  Google Scholar 

  10. Camus M, Siemiatycki J, Meek B. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. N Engl J Med 1998;338:1565–1571.

    Article  PubMed  CAS  Google Scholar 

  11. McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer 1980;46: 1650–1656.

    Article  PubMed  CAS  Google Scholar 

  12. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2–17.

    Article  PubMed  CAS  Google Scholar 

  13. Carbone M, Pass HI, Miele L, Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene 2003;22:5173–5180.

    Article  PubMed  CAS  Google Scholar 

  14. Foddis R, De Rienzo A, Broccoli D, et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002;21:1434–1442.

    Article  PubMed  CAS  Google Scholar 

  15. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357:444–445.

    Article  PubMed  CAS  Google Scholar 

  16. Austin MB, Fechner RE, Roggli VL. Pleural malignant mesothelioma following Wilms’ tumor. Am J Clin Pathol 1986;86:227–230.

    PubMed  CAS  Google Scholar 

  17. Sanders CL, Jackson TA. Induction of mesotheliomas and sarcomas from “hot spots” of 239 PuO 2 activity. Health Phys 1972;22:755–759.

    Article  PubMed  CAS  Google Scholar 

  18. Powell JE, Stevens MC, Stiller CA. Clustering of childhood peritoneal mesothelioma in the Midlands, UK. Lancet 1995;345:66–67.

    Article  PubMed  CAS  Google Scholar 

  19. Kelsey A. Mesothelioma in childhood. Pediatr Hematol Oncol 1994;11:461–462.

    PubMed  CAS  Google Scholar 

  20. Niggli FK, Gray TJ, Raafat F, Stevens MC. Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry. Pediatr Hematol Oncol 1994; 11:399–408.

    PubMed  CAS  Google Scholar 

  21. Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004; 14:447–460.

    PubMed  Google Scholar 

  22. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183–1200.

    Article  PubMed  CAS  Google Scholar 

  23. Suzuki Y. Diagnostic criteria for human diffuse malignant mesothelioma. Acta Pathol Jpn 1992;42:767–786.

    PubMed  CAS  Google Scholar 

  24. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol 1977;8:83–94.

    Article  PubMed  CAS  Google Scholar 

  25. Dhaene K, Hubner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax 1998;53:915–918.

    Article  PubMed  CAS  Google Scholar 

  26. Dhaene K, Wauters J, Weyn B, Timmermans JP, Van Marck E. Expression profile of telomerase subunits in human pleural mesothelioma. J Pathol 2000;190:80–85.

    Article  PubMed  CAS  Google Scholar 

  27. Kumaki F, Kawai T, Churg A, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002;26:365–370.

    Article  PubMed  Google Scholar 

  28. Rosai J. Rosai and Ackerman’sSurgical Pathology. 9th ed. Edinburgh-London-New York: Mosby-Elsevier; 2004.

    Google Scholar 

  29. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929–933.

    PubMed  CAS  Google Scholar 

  30. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476–481.

    Article  PubMed  Google Scholar 

  31. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61:924–926.

    PubMed  CAS  Google Scholar 

  32. Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996;81:193–211.

    PubMed  CAS  Google Scholar 

  33. Kebapci M, Vardareli E, Adapinar B, Acikalin M. CT findings and serum CA 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003;13: 2620–2626.

    Article  PubMed  Google Scholar 

  34. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981;8:313–320.

    PubMed  CAS  Google Scholar 

  35. van Gelder T, Hoogsteden HC, Versnel MA, de Beer P, Vandenbroucke JP, Planteydt HT. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989;43:222–227.

    Article  PubMed  Google Scholar 

  36. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980;68:356–362.

    Article  PubMed  CAS  Google Scholar 

  37. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003;23:531–536.

    PubMed  CAS  Google Scholar 

  38. Dahl IM, Solheim OP, Erikstein B, Muller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer 1989;64:68–73.

    Article  PubMed  CAS  Google Scholar 

  39. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104–2107.

    Article  PubMed  CAS  Google Scholar 

  40. Ros PR, Yuschok TJ, Buck JL, Shekitka KM, Kaude JV. Peritoneal mesothelioma. Radiologie appearances correlated with histology. Acta Radiol 1991;32:355–358.

    Article  PubMed  CAS  Google Scholar 

  41. Antman K, Pomfret F, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983;1:386.

    PubMed  CAS  Google Scholar 

  42. Plaus WJ. Peritoneal mesothelioma. Arch Surg 1988;123:763–766.

    PubMed  CAS  Google Scholar 

  43. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89:269–273.

    PubMed  Google Scholar 

  44. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103: 839–849.

    Article  PubMed  Google Scholar 

  45. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous cacinomas. Am J Surg Pathol 1998;22:1203–1214.

    Article  PubMed  CAS  Google Scholar 

  46. Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30:313–323.

    Article  PubMed  CAS  Google Scholar 

  47. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253–262.

    Article  PubMed  CAS  Google Scholar 

  48. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237–244.

    Article  PubMed  CAS  Google Scholar 

  49. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary andnonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598–606.

    Article  PubMed  CAS  Google Scholar 

  50. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151–155.

    Article  PubMed  Google Scholar 

  51. Ruan Q, Hu Y. Immunophenotypings of malignant epithelial mesothelioma and their roles in the differential diagnosis. J Huazhong Univ Sci Techn Med Sci 2004;24:112–115.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, Bethesda, MD

    David P. Mangiameli MD, Steven K. Libutti MD, James F. Pingpank MD & H. Richard Alexander MD

Authors
  1. David P. Mangiameli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven K. Libutti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James F. Pingpank MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Richard Alexander MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

  2. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) & Ulrike Stein PhD (Assistant Professor) (Professor and Head of Surgical Oncology) &  (Assistant Professor)

  3. Tumor Metastasis and Therapy Response Program, Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Ulrike Stein PhD (Assistant Professor) (Assistant Professor)

  4. Erasmus University MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Alexander M. M. Eggermont MD, PhD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Mangiameli, D.P., Libutti, S.K., Pingpank, J.F., Alexander, H.R. (2007). Malignant Peritoneal Mesothelioma. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-225-0_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-672-6

  • Online ISBN: 978-1-59745-225-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation